379229-84-2

Basic information

• Product Name: TERT-BUTYL (5-CHLORO-1,3-BENZODIOXOL-4-YL)CARBAMATE
• Synonyms: TERT-BUTYL (5-CHLORO-1,3-BENZODIOXOL-4-YL)CARBAMATE;tert-butyl 5-chlorobenzo[d][1,3]dioxol-4-ylcarbamate;CarbaMic acid, (5-chloro-1,3-benzodioxol-4-yl)-, 1,1-diMethylethyl ester (9CI);CarbaMic acid, (5-chloro-1,3-benzodioxol-4-yl)-, 1,1-diMethylethyl ester
• CAS NO: 379229-84-2
• Molecular Formula: C₁₂H₁₄ClNO₄
• Molecular Weight: 271.69686
• Mol File: 379229-84-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 309.791 °C at 760 mmHg
• Flash Point: 141.157 °C
• Appearance: /
• Density: 1.347
• CAS DataBase Reference: TERT-BUTYL (5-CHLORO-1,3-BENZODIOXOL-4-YL)CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL (5-CHLORO-1,3-BENZODIOXOL-4-YL)CARBAMATE(379229-84-2)
• EPA Substance Registry System: TERT-BUTYL (5-CHLORO-1,3-BENZODIOXOL-4-YL)CARBAMATE(379229-84-2)

Safety Data

• Hazardous Substances Data: 379229-84-2(Hazardous Substances Data)

Usage

General Description

Tert-butyl (5-chloro-1,3-benzodioxol-4-yl)carbamate is a chemical compound that is commonly used as a reagent in organic synthesis and medicinal chemistry. It is a derivative of carbamic acid and contains a tert-butyl group, a chloro substituent, and a benzodioxol ring. tert-Butyl (5-chloro-1,3-benzodioxol-4-yl)carbamate has been studied for its potential use in the development of pharmaceutical drugs, particularly in the field of neurology. Its unique structure and properties make it a valuable tool for researchers and chemists working in the area of drug discovery and development.

Upstream product

• 75-65-0 tert-butyl alcohol 
• 379229-83-1 5-chloro-1,3-benzodioxole-4-carboxylic acid 
• 7228-38-8 5-chloro-1,3-benzodioxole 

Downstream Products

• 379228-45-2 5-chlorobenzo[d][1,3]dioxolcyclopenten-4-amine 

Relevant articles and documents

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS

The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.